| Project/Area Number |
22791241
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Radiation science
|
|---|
| Research Institution | 公益財団法人先端医療振興財団 (2011)
Foundation for Biomedical Research and Innovation (2010) |
|---|
Principal Investigator |
YAMANE Tomohiko 公益財団法人先端医療振興財団, 映像医療研究開発部門分子イメージング研究グループ, 医師 (20526660)
|
|---|
| Project Period (FY) |
2010 – 2011
|
| Project Status |
Completed (Fiscal Year 2011)
|
| Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2011: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Fiscal Year 2010: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | FLT-PET / 子宮筋腫 / FDG-PET / 子宮肉腫 |
|---|
| Research Abstract |
The aim of this study is to test the hypothesis that positron emission tomography(PET) with 3'-deoxy-3'-[^<18> F]-fluorothymidine(^<18> F-FLT) can differentiate malignancy from benign leiomyoma better than PET with 2-deoxy-2-[^<18> F] fluoro-D-glucose(^<18> F-FDG), and to evaluate whether^<18> F-FLT and^<18> F-FDG uptake correlate with immunohistochemical index of cell proliferation. In conclusion, negative findings on additional^<18> F-FDG or^<18> F-FLT PET may rule out the possibility of malignancy for the patients with suspected leiomyosarcoma diagnosed by conventional methods.^<18> F-FLT PET is superior to^<18> F-FDG PET in differentiating malignant from benign leiomyoma. Moreover,^<18> F-FLT uptake correlated well with the immunohistochemical index of cell proliferation.
|
